Her2 treatment drugs

The treatment paradigm in HER2-positive advanced BC (ABC) has been increasingly transformed since the development of several additional HER2-targeted drugs. HER2-targeting represents the treatment cornerstone in this setting, including monoclonal antibodies, tyrosine kinase inhibitors and, recently, antibody drug conjugates (ADCs).

drug's reach. The FDA granted the designation to Enhertu as a potential treatment for certain patients with HER2-low or HER2-ultralow breast cancer. The

Background: Treatment of HER2-positive (HER2) breast cancer is based on the use of drugs targeting HER2 (anti-HER2 treatment). Trastuzumab is the current

HER2-positive breast cancers have a lot of a protein called HER2 on the surface of their cells. The HER2 protein is an important driver of cell growth and survival. HER2-targeted therapies are designed to treat HER2-positive breast cancers. They have no role in the treatment of HER2-negative cancers. Testing for HER2 status

Exploring HER2 Targeting: Transforming Treatment for Metastatic and Locally Advanced HER2 Cancers. The emergence of HER2-targeted antibody-drug conjugates

There are many ongoing studies of potential HER2-mutant lung cancer treatments that are very exciting, Dr. Li said. Some are looking at other antibody drug conjugates that bind to HER2 or new small-molecule drugs that block the activity of HER2.

by SM Swain 2024 Cited by 399With these successes, trastuzumab became firmly established as the treatment of choice for patients with HER2 BC, and HER2 drug development

The first anti-HER2 drug, Herceptin, received approval in 2024 to treat HER2-positive breast cancer. Since then, many more anti-HER2 drugs have joined the list of approved treatments.

HER2 amplification-positive patients might benefit from existing HER2-targeted drugs, but some HER2 mutations result in resistance to the same treatments 6,11,12,13.